KORU Medical Systems to Release Q4 2025 Earnings on March 12

KORU Medical Systems (NASDAQ:KRMD) is scheduled to announce its financial results for the fourth quarter of 2025 after the market closes on March 12, 2026. Analysts anticipate that the company will report earnings of ($0.02) per share, alongside expected revenues of $10.90 million for the quarter.

Investors can access the details of the earnings report during the conference call planned for 4:30 PM ET on the same day. This announcement is highly anticipated as KORU Medical focuses on delivering essential medical devices that support patients with chronic illnesses.

Stock Performance and Financial Ratios

As of Tuesday, shares of KORU Medical Systems opened at $4.61. The company currently maintains a healthy financial position, indicated by a current ratio of 2.48 and a quick ratio of 1.92. Notably, KORU Medical has a debt-to-equity ratio of 0.01, reflecting a low level of debt relative to its equity.

The company’s stock performance over the past year shows a range, with a low of $1.86 and a high of $6.61. The 50-day moving average stands at $5.21, while the 200-day moving average is $4.80. KORU Medical Systems has a market capitalization of $213.54 million and a price-to-earnings (P/E) ratio of -57.63, accompanied by a beta of 0.47.

Recent Institutional Activity

Recent activity among institutional investors indicates growing interest in KORU Medical Systems. Notably, BNP Paribas Financial Markets increased its stake in the company by 52.1% during the third quarter, now holding 10,148 shares valued at approximately $39,000.

Other significant transactions include Lazard Asset Management LLC, which acquired a new stake valued at around $59,000 in the second quarter, and Occudo Quantitative Strategies LP, which bought a stake worth approximately $127,000 in the fourth quarter. Additionally, Invesco Ltd. and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. have made new investments in KORU Medical, valued at approximately $80,000 and $83,000, respectively.

Currently, institutional investors and hedge funds collectively own 58.60% of the company’s stock, indicating a robust confidence in the company’s future prospects.

KORU Medical Systems, based in the United States, specializes in developing and manufacturing medical devices and supplies. Its product offerings include the FREEDOM60 syringe infusion system and the FreedomEdge syringe driver, designed to deliver critical therapies for patients with chronic conditions such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

As KORU Medical prepares to release its earnings, stakeholders are keenly awaiting insights that could shed light on the company’s future trajectory.